Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era
-
Published:2023-12
Issue:6
Volume:21
Page:e438-e448
-
ISSN:1558-7673
-
Container-title:Clinical Genitourinary Cancer
-
language:en
-
Short-container-title:Clinical Genitourinary Cancer
Author:
Holmsten KarinORCID, Eknert Johanna, Öfverholm Elisabeth, Papantoniou DimitriosORCID, Jawdat Faith, Verbiéné Ingrida, Laurell Anna, Jänes Elin, Sandzén Johan, Wojtyna-Dziedzic Elzbieta, Lagstam Ida, Söderkvist KarinORCID, Costa Svedman FernandaORCID, Liedberg Fredrik, Bruzelius Martin, Fransson Ann-Sofie, Kjellström Sofia, Omland Lise HoejORCID, Pappot Helle, Ullén Anders
Reference31 articles.
1. Avelumab Maintenance therapy for advanced or metastatic urothelial carcinoma;Powles;N Eng J Med,2020 2. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924 3. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer;von der Maase;J Clin Oncol,2005 4. Pembrolizumab as second-line therapy for advanced urothelial carcinoma;Bellmunt;N Engl J Med,2017 5. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial;Powles;Lancet Oncol,2021
|
|